The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I trial of IMC-A12 and temsirolimus in children with refractory solid tumors: A Children’s Oncology Group Study.
M. Fouladi
No relevant relationships to disclose
J. P. Perentesis
No relevant relationships to disclose
L. M. Wagner
No relevant relationships to disclose
A. M. Ingle
No relevant relationships to disclose
J. Gammon
No relevant relationships to disclose
G. Thomas
No relevant relationships to disclose
D. A. Krueger
Consultant or Advisory Role - Novartis (U)
Honoraria - Novartis
Research Funding - Novartis
P. Houghton
No relevant relationships to disclose
S. Vinks
No relevant relationships to disclose
B. Weigel
No relevant relationships to disclose
S. Blaney
No relevant relationships to disclose